Prospective observation: Clinical utility of plasma Epstein–Barr virus DNA load in EBV-associated gastric carcinoma patients

Miao Zhen Qiu, Cai Yun He, Shi Xun Lu, Wen Long Guan, Fang Wang, Xiao Jian Wang, Ying Jin, Feng Hua Wang, Yu Hong Li, Jian Yong Shao, Zhi Wei Zhou, Jing Ping Yun, Rui Hua Xu

Research output: Contribution to journalArticle

Abstract

Epstein–Barr virus (EBV)-associated gastric carcinomas (EBVaGCs) may account for 8–9% of all gastric cancer (GC) patients. All previous reports on EBVaGC were retrospective. Prospective study is warranted to evaluate the exact role of EBV status in predicting the prognosis of GC. It is of special interest to figure out whether dynamic detection of plasma EBV-DNA load could be a feasible biomarker for the monitor of EBVaGC. From October 2014 to September 2017, we consecutively collected GC patients (n = 2,760) from Sun Yat-sen University Cancer Center for EBER examination. We detected EBV-DNA load in plasma and tissue samples of EBVaGC patients at baseline. Subsequently, plasma EBV-DNA load was dynamically monitored in EBVaGC patients. The overall prevalence of EBVaGC is 5.1% (140/2,760). The incidence rate of EBVaGC decreased with advanced AJCC 7th TNM stage (p < 0.001), with the corresponding percentages of 9.3, 9.9, 6.7 and 1.4% for Stage I, II, III and IV patients. EBVaGC patients were predominately young males with better histologic differentiation and earlier TNM stage than EBV-negative GC (EBVnGC) patients. EBVaGC patients were confirmed to had a favorable 3-year survival rate (EBVaGC vs. EBVnGC: 76.8% vs. 58.2%, p = 0.0001). Though only 52.1% (73/140) EBVaGC patients gained detectable EBV-DNA and 43.6% (61/140) reached a positive cutoff of 100 copies/ml, we found the plasma EBV-DNA load in EBVaGC decreased when patients got response, while it increased when disease progressed. Our results suggested that plasma EBV-DNA is a good marker in predicting recurrence and chemotherapy response for EBVaGC patients.

Original languageEnglish (US)
Pages (from-to)272-280
Number of pages9
JournalInternational Journal of Cancer
Volume146
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

DNA Viruses
Human Herpesvirus 4
Stomach
Observation
Viruses
Carcinoma
Stomach Neoplasms
Solar System
Survival Rate

Keywords

  • EBV
  • EBV-DNA
  • gastric cancer
  • prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prospective observation : Clinical utility of plasma Epstein–Barr virus DNA load in EBV-associated gastric carcinoma patients. / Qiu, Miao Zhen; He, Cai Yun; Lu, Shi Xun; Guan, Wen Long; Wang, Fang; Wang, Xiao Jian; Jin, Ying; Wang, Feng Hua; Li, Yu Hong; Shao, Jian Yong; Zhou, Zhi Wei; Yun, Jing Ping; Xu, Rui Hua.

In: International Journal of Cancer, Vol. 146, No. 1, 01.01.2020, p. 272-280.

Research output: Contribution to journalArticle

Qiu, Miao Zhen ; He, Cai Yun ; Lu, Shi Xun ; Guan, Wen Long ; Wang, Fang ; Wang, Xiao Jian ; Jin, Ying ; Wang, Feng Hua ; Li, Yu Hong ; Shao, Jian Yong ; Zhou, Zhi Wei ; Yun, Jing Ping ; Xu, Rui Hua. / Prospective observation : Clinical utility of plasma Epstein–Barr virus DNA load in EBV-associated gastric carcinoma patients. In: International Journal of Cancer. 2020 ; Vol. 146, No. 1. pp. 272-280.
@article{8c56abe23bb1491a96350a8063840ed0,
title = "Prospective observation: Clinical utility of plasma Epstein–Barr virus DNA load in EBV-associated gastric carcinoma patients",
abstract = "Epstein–Barr virus (EBV)-associated gastric carcinomas (EBVaGCs) may account for 8–9{\%} of all gastric cancer (GC) patients. All previous reports on EBVaGC were retrospective. Prospective study is warranted to evaluate the exact role of EBV status in predicting the prognosis of GC. It is of special interest to figure out whether dynamic detection of plasma EBV-DNA load could be a feasible biomarker for the monitor of EBVaGC. From October 2014 to September 2017, we consecutively collected GC patients (n = 2,760) from Sun Yat-sen University Cancer Center for EBER examination. We detected EBV-DNA load in plasma and tissue samples of EBVaGC patients at baseline. Subsequently, plasma EBV-DNA load was dynamically monitored in EBVaGC patients. The overall prevalence of EBVaGC is 5.1{\%} (140/2,760). The incidence rate of EBVaGC decreased with advanced AJCC 7th TNM stage (p < 0.001), with the corresponding percentages of 9.3, 9.9, 6.7 and 1.4{\%} for Stage I, II, III and IV patients. EBVaGC patients were predominately young males with better histologic differentiation and earlier TNM stage than EBV-negative GC (EBVnGC) patients. EBVaGC patients were confirmed to had a favorable 3-year survival rate (EBVaGC vs. EBVnGC: 76.8{\%} vs. 58.2{\%}, p = 0.0001). Though only 52.1{\%} (73/140) EBVaGC patients gained detectable EBV-DNA and 43.6{\%} (61/140) reached a positive cutoff of 100 copies/ml, we found the plasma EBV-DNA load in EBVaGC decreased when patients got response, while it increased when disease progressed. Our results suggested that plasma EBV-DNA is a good marker in predicting recurrence and chemotherapy response for EBVaGC patients.",
keywords = "EBV, EBV-DNA, gastric cancer, prognosis",
author = "Qiu, {Miao Zhen} and He, {Cai Yun} and Lu, {Shi Xun} and Guan, {Wen Long} and Fang Wang and Wang, {Xiao Jian} and Ying Jin and Wang, {Feng Hua} and Li, {Yu Hong} and Shao, {Jian Yong} and Zhou, {Zhi Wei} and Yun, {Jing Ping} and Xu, {Rui Hua}",
year = "2020",
month = "1",
day = "1",
doi = "10.1002/ijc.32490",
language = "English (US)",
volume = "146",
pages = "272--280",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Prospective observation

T2 - Clinical utility of plasma Epstein–Barr virus DNA load in EBV-associated gastric carcinoma patients

AU - Qiu, Miao Zhen

AU - He, Cai Yun

AU - Lu, Shi Xun

AU - Guan, Wen Long

AU - Wang, Fang

AU - Wang, Xiao Jian

AU - Jin, Ying

AU - Wang, Feng Hua

AU - Li, Yu Hong

AU - Shao, Jian Yong

AU - Zhou, Zhi Wei

AU - Yun, Jing Ping

AU - Xu, Rui Hua

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Epstein–Barr virus (EBV)-associated gastric carcinomas (EBVaGCs) may account for 8–9% of all gastric cancer (GC) patients. All previous reports on EBVaGC were retrospective. Prospective study is warranted to evaluate the exact role of EBV status in predicting the prognosis of GC. It is of special interest to figure out whether dynamic detection of plasma EBV-DNA load could be a feasible biomarker for the monitor of EBVaGC. From October 2014 to September 2017, we consecutively collected GC patients (n = 2,760) from Sun Yat-sen University Cancer Center for EBER examination. We detected EBV-DNA load in plasma and tissue samples of EBVaGC patients at baseline. Subsequently, plasma EBV-DNA load was dynamically monitored in EBVaGC patients. The overall prevalence of EBVaGC is 5.1% (140/2,760). The incidence rate of EBVaGC decreased with advanced AJCC 7th TNM stage (p < 0.001), with the corresponding percentages of 9.3, 9.9, 6.7 and 1.4% for Stage I, II, III and IV patients. EBVaGC patients were predominately young males with better histologic differentiation and earlier TNM stage than EBV-negative GC (EBVnGC) patients. EBVaGC patients were confirmed to had a favorable 3-year survival rate (EBVaGC vs. EBVnGC: 76.8% vs. 58.2%, p = 0.0001). Though only 52.1% (73/140) EBVaGC patients gained detectable EBV-DNA and 43.6% (61/140) reached a positive cutoff of 100 copies/ml, we found the plasma EBV-DNA load in EBVaGC decreased when patients got response, while it increased when disease progressed. Our results suggested that plasma EBV-DNA is a good marker in predicting recurrence and chemotherapy response for EBVaGC patients.

AB - Epstein–Barr virus (EBV)-associated gastric carcinomas (EBVaGCs) may account for 8–9% of all gastric cancer (GC) patients. All previous reports on EBVaGC were retrospective. Prospective study is warranted to evaluate the exact role of EBV status in predicting the prognosis of GC. It is of special interest to figure out whether dynamic detection of plasma EBV-DNA load could be a feasible biomarker for the monitor of EBVaGC. From October 2014 to September 2017, we consecutively collected GC patients (n = 2,760) from Sun Yat-sen University Cancer Center for EBER examination. We detected EBV-DNA load in plasma and tissue samples of EBVaGC patients at baseline. Subsequently, plasma EBV-DNA load was dynamically monitored in EBVaGC patients. The overall prevalence of EBVaGC is 5.1% (140/2,760). The incidence rate of EBVaGC decreased with advanced AJCC 7th TNM stage (p < 0.001), with the corresponding percentages of 9.3, 9.9, 6.7 and 1.4% for Stage I, II, III and IV patients. EBVaGC patients were predominately young males with better histologic differentiation and earlier TNM stage than EBV-negative GC (EBVnGC) patients. EBVaGC patients were confirmed to had a favorable 3-year survival rate (EBVaGC vs. EBVnGC: 76.8% vs. 58.2%, p = 0.0001). Though only 52.1% (73/140) EBVaGC patients gained detectable EBV-DNA and 43.6% (61/140) reached a positive cutoff of 100 copies/ml, we found the plasma EBV-DNA load in EBVaGC decreased when patients got response, while it increased when disease progressed. Our results suggested that plasma EBV-DNA is a good marker in predicting recurrence and chemotherapy response for EBVaGC patients.

KW - EBV

KW - EBV-DNA

KW - gastric cancer

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=85067876920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067876920&partnerID=8YFLogxK

U2 - 10.1002/ijc.32490

DO - 10.1002/ijc.32490

M3 - Article

C2 - 31162842

AN - SCOPUS:85067876920

VL - 146

SP - 272

EP - 280

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -